Clinical Trial Update: Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating anakinra for chronically inflamed white matter lesions in multiple sclerosis has completed, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• KINERET (ANAKINRA)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Multiple Sclerosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-12-27